Kymera Therapeutics (KYMR) Consolidated Net Income (2019 - 2026)

Kymera Therapeutics (KYMR) has reported Consolidated Net Income for 8 consecutive years, with -$494.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Consolidated Net Income fell 151.9% year-over-year to -$494.8 million; the TTM figure through Mar 2026 stood at -$1.2 billion (down 90.29% YoY), while the FY2025 annual figure was -$749.9 million, down 50.63% from the prior year.
• Consolidated Net Income retreated to -$494.8 million in Q1 2026 per KYMR's latest filing, from -$97.9 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at -$38.7 million in Q4 2022 and bottomed at -$494.8 million in Q1 2026.
• Historically, Consolidated Net Income has averaged -$168.8 million across 5 years, with a median of -$166.9 million in 2023.
• Annual changes were most pronounced in 2022 — Consolidated Net Income soared 65.08% — and 2026, when it tumbled 151.9%.
• Kymera Therapeutics' Consolidated Net Income stood at -$38.7 million in 2022, then slumped by 78.16% to -$68.9 million in 2023, then retreated by 17.17% to -$80.8 million in 2024, then declined by 21.2% to -$97.9 million in 2025, then tumbled by 405.39% to -$494.8 million in 2026.
• Business Quant data shows KYMR's Consolidated Net Income at -$494.8 million in Q1 2026, -$97.9 million in Q4 2025, and -$342.6 million in Q3 2025.